Novartis' Urticaria drug Xolair obtains EU approval

Novartis has received approval from the European Commission (EC) to use Xolair (omalizumab) as an add-on therapy to treat chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years and above with inadequate response to H1-antihista…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news